Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.26 -2.3%	$1.46	$1.13 ▼ $2.66	$112.44M	2.61	389,566 shs	114,992 shs
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
SCPH scPharmaceuticals	$2.42 -3.6%	$2.64	$1.94 ▼ $5.65	$121.69M	0.17	357,222 shs	149,928 shs
SLN Silence Therapeutics	$3.70 +3.9%	$3.39	$1.97 ▼ $24.38	$110.74M	1.2	297,683 shs	109,975 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	+3.61%	-15.13%	+9.32%	-49.81%	-39.44%
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	+6.98%
SCPH scPharmaceuticals	+4.37%	-0.79%	+16.74%	-22.77%	-46.48%
SLN Silence Therapeutics	-4.91%	-11.22%	+54.78%	-28.94%	-84.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.3852 of 5 stars	3.5	4.0	0.0	0.0	0.0	0.0
IGXT IntelGenx Technologies	0.2925 of 5 stars	0.0	3.0	0.0	0.6	1.7	0.0
SCPH scPharmaceuticals	3.5156 of 5 stars	3.5	0.0	4.2	2.4	1.7	0.6
SLN Silence Therapeutics	2.5735 of 5 stars	4.4	1.0	0.0	2.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	217.46% Upside
IGXT IntelGenx Technologies	0.00	N/A	N/A	N/A
SCPH scPharmaceuticals	3.00	Buy	$14.00	478.51% Upside
SLN Silence Therapeutics	2.71	Moderate Buy	$33.83	814.41% Upside

Current Analyst Ratings Breakdown

Latest IGXT, SCPH, CGEN, and SLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$4.00 ➝ $3.00
5/9/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $25.00
5/9/2025	SLN Silence Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $35.00
3/20/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $12.00
3/20/2025	SCPH scPharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/7/2025	SLN Silence Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/5/2025	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$49.00 ➝ $45.00
3/4/2025	SLN Silence Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$67.00 ➝ $25.00
3/4/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$6.00 ➝ $4.00
3/3/2025	SCPH scPharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
2/11/2025	SLN Silence Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	4.04	N/A	N/A	$0.73 per share	1.73
IGXT IntelGenx Technologies	$1.04M	28.05	N/A	N/A	($0.07) per share	-2.39
SCPH scPharmaceuticals	$36.33M	3.35	N/A	N/A	$1.04 per share	2.33
SLN Silence Therapeutics	$43.26M	2.56	N/A	N/A	$0.71 per share	5.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$18.75M	-$0.16	63.00	N/A	N/A	2.67%	2.62%	1.36%	5/19/2025 (Estimated)
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	N/A	N/A	N/A	5/13/2025 (Estimated)
SCPH scPharmaceuticals	-$54.81M	-$1.90	N/A	N/A	N/A	-264.60%	-244.93%	-68.56%	5/13/2025 (Estimated)
SLN Silence Therapeutics	-$53.82M	-$0.95	N/A	N/A	N/A	-342.00%	-62.81%	-33.89%	5/15/2025 (Estimated)

Latest IGXT, SCPH, CGEN, and SLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	N/A	N/A	N/A	$3.70 million	N/A
5/15/2025	Q1 2025	SLN Silence Therapeutics	-$0.18	-$0.60	-$0.42	-$0.60	$3.58 million	$0.14 million
5/13/2025	Q1 2025	SCPH scPharmaceuticals	-$0.28	N/A	N/A	N/A	$11.63 million	N/A
3/19/2025	Q4 2024	SCPH scPharmaceuticals	-$0.40	-$0.35	+$0.05	-$0.35	$12.08 million	$12.15 million
3/4/2025	Q4 2024	CGEN Compugen	$0.07	-$0.07	-$0.14	-$0.07	$17.47 million	$1.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.14	4.14
IGXT IntelGenx Technologies	N/A	N/A	N/A
SCPH scPharmaceuticals	1.66	8.08	6.89
SLN Silence Therapeutics	N/A	9.31	9.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
IGXT IntelGenx Technologies	N/A
SCPH scPharmaceuticals	89.52%
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
IGXT IntelGenx Technologies	42.05%
SCPH scPharmaceuticals	5.52%
SLN Silence Therapeutics	2.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
IGXT IntelGenx Technologies	38	174.66 million	101.21 million	Not Optionable
SCPH scPharmaceuticals	30	50.28 million	47.28 million	Optionable
SLN Silence Therapeutics	100	29.93 million	N/A	Not Optionable

IGXT, SCPH, CGEN, and SLN Headlines

Recent News About These Companies

Silence Therapeutics plc GAAP EPS of -C$0.20

May 8 at 10:16 AM | seekingalpha.com

Cantor Fitzgerald L. P. Buys 205,534 Shares of Silence Therapeutics plc (NASDAQ:SLN)

May 7 at 6:53 AM | marketbeat.com

Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6 at 5:17 PM | finanznachrichten.de

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6 at 7:45 AM | businesswire.com

Silence Therapeutics plc (NASDAQ:SLN) Stock Holdings Increased by Nantahala Capital Management LLC

April 30, 2025 | marketbeat.com

Boothbay Fund Management LLC Has $2.42 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

April 30, 2025 | marketbeat.com

Marshall Wace LLP Purchases 320,472 Shares of Silence Therapeutics plc (NASDAQ:SLN)

April 28, 2025 | marketbeat.com

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

April 23, 2025 | insidermonkey.com

Silence Therapeutics plc (NASDAQ:SLN) Given Average Rating of "Moderate Buy" by Brokerages

April 20, 2025 | marketbeat.com

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

March 5, 2025 | businesswire.com

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

March 4, 2025 | zacks.com

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2025 | uk.finance.yahoo.com

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

February 28, 2025 | seekingalpha.com

Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner

February 28, 2025 | biospace.com

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

February 27, 2025 | businesswire.com

Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation

February 11, 2025 | msn.com

Silence Therapeutics hit with new Sell at Goldman Sachs on resource constraints

February 11, 2025 | seekingalpha.com

Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

February 11, 2025 | markets.businessinsider.com

Silence Therapeutics initiated with a Sell at Goldman Sachs

February 11, 2025 | markets.businessinsider.com

Goldman Sachs cuts Silence Therapeutics stock rating to Sell

February 11, 2025 | msn.com

(SLN) Investment Analysis

January 17, 2025 | news.stocktradersdaily.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, SCPH, CGEN, and SLN Company Descriptions

Compugen NASDAQ:CGEN

$1.26 -0.03 (-2.33%)

As of 04:00 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)

As of 05/8/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

scPharmaceuticals NASDAQ:SCPH

$2.42 -0.09 (-3.59%)

As of 03:52 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$3.70 +0.14 (+3.93%)

As of 03:58 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time